Author(s): Prof Georg Lenz, MD1; Prof Marek Trněný, MD2; John M Burke, MD3; Prof Grzegorz S Nowakowski, MD4; Prof Christopher P Fox, MD5; Annalisa Chiappella, MD6; Johannes Duell, MD7; Young Woo Jeon, MD8; Prof Chan Y Cheah, MD9; Jason Westin, MD10; Joseph Z Ye, MD11; Priscilla B Caguioa, MD12; David Belada, MD13; Ho-Jin Shin, MD14; Prof Sung Yong Oh, MD15; Sandy Amorim, MD16; Matthew Ku, MBBS17; Heidi Mocikova, MD18; Javier López Jiménez, MD19; Prof Gianluca Gaidano, MD20; Andreas Rosenwald, MD21; Roberto Chiarle, MD22,23; Philomena Colucci, DO24; Sonia Ioannidis, PhD25; Lulu Cheng, PhD24; Umberto Vitolo, MD26;
BACKGROUND
Approximately 40% of patients with high-risk diffuse large B-cell lymphoma (DLBCL) are not cured with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone). We aimed to investigate the addition of tafasitamab (an Fc-enhanced anti-CD19 monoclonal antibody) and lenalidomide to R-CHOP (tafa-len-R-CHOP) in patients with high-risk aggressive B-cell lymphomas.
METHODS
frontMIND is a phase 3, randomised, double-blind, placebo-controlled study conducted 298 centres in North America, South America, Europe, and the Asia–Pacific region. Patients aged 18–80 years with previously untreated, high-intermediate-risk or high-risk DLBCL or high-grade B-cell lymphoma (HGBL) were randomly allocated (1:1), stratified by International Prognostic Index (IPI) or age-adjusted IPI and geographical region, to receive six 21-day cycles of standard R-CHOP (rituximab 375 mg/m2 intravenous on day 1, cyclophosphamide 750 mg/m2 intravenous on day 1, doxorubicin 50 mg/m2 intravenous on day 1, vincristine 1·4 mg/m2 [maximum 2 mg] intravenous on day 1, and prednisone or prednisolone 100 mg/day orally on days 1–5); patients in the tafa-len-R-CHOP group additionally received tafasitamab (12 mg/kg intravenous on days 1, 8, and 15) plus lenalidomide (25 mg/day orally on days 1–10), while those in the R-CHOP group received matching placebos. The primary endpoint was investigator-assessed progression-free survival (defined as time from randomisation to disease progression or death from any cause), analysed in the intention-to-treat population; safety was included as a secondary endpoint among all patients who received least one dose of study treatment. The trial is registered with ClinicalTrials.gov (NCT04824092) and EUDRA-CT (2020-002990-84) and is active but no longer enrolling.
FINDINGS
Between May 11, 2021, and March 2, 2023, 1229 patients were screened, among whom 899 were randomly allocated: 448 (50%) to the tafa-len-R-CHOP group and 451 (50%) to the R-CHOP group. the time of primary analysis (median follow-up 35·2 months [95% CI 35·0–35·4]), progression-free survival was improved in the tafa-len-R-CHOP group versus the R-CHOP group (hazard ratio [HR] 0·75 [95% CI 0·59–0·96]; p=0·0194), with 2-year progression-free survival rates of 71·1% (66·3–75·4) with tafa-len-R-CHOP versus 62·9% (57·9–67·5) with R-CHOP. Interim HR for overall survival was 0·85 (0·63–1·14). The overall rate of grade 3 or higher treatment-emergent adverse events was higher with tafa-len-R-CHOP (384 [87%] of 443) than with R-CHOP (340 [76%] of 447). Additionally, a higher rate of fatal treatment-emergent adverse events was observed with tafa-len-R-CHOP (26 [6%]) than with R-CHOP (17 [4%]). However, the number of overall deaths in the study was lower with tafa-len-R-CHOP than with R-CHOP (82 [19%] vs 97 [22%]). Based on disposition data, rates of premature discontinuation of all study drugs were similar in the tafa-len-R-CHOP group (71 [16%] of 443) and R-CHOP group (66 [15%] of 447).
INTERPRETATION
Progression-free survival was significantly improved with tafa-len-R-CHOP versus R-CHOP; however, the safety profile indicated increases in adverse events, including treatment-emergent adverse events leading to death, with the addition of tafasitamab and lenalidomide. Overall survival data are immature; follow-up is ongoing. Further analyses, including of circulating tumor DNA, will help to assess whether deeper molecular responses are contributing to the progression-free survival benefit observed with tafa-len-R-CHOP. Tafa-len-R-CHOP might represent a potential new first-line treatment for patients with high-risk DLBCL or HGBL.
Author Affiliations
1Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany; 2First Faculty of Medicine, Charles University, Prague, Czechia; 3Sarah Cannon Research Institute Rocky Mountain Cancer Centers, Aurora, CO, United States of America; 4Division of Hematology, Mayo Clinic, Rochester, MN, United States of America; 5School of Medicine, University of Nottingham, and Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom of Great Britain and Northern Ireland (the); 6Fondazione IRCCS Istituto Nazionale dei Tumori, Hematology, Milan, Italy; 7Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany; 8Department of Hematology, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea (the Republic of); 9Hollywood Private Hospital and University of Western Australia, Nedlands, WA, Australia; 10MD Anderson Cancer Center, Houston, TX, United States of America; 11American Oncology Network, Vista Oncology Division, Olympia, WA, United States of America; 12St Luke's Medical Center, Quezon, Philippines; 13Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czechia; 14Division of Hematology-Oncology, Department of Internal Medicine, Research Institute of Medical Science, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea (the Republic of); 15Division of Hematology-Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea (the Republic of); 16Department of Hematology and Cellular Therapy, Hôpital Saint Vincent de Paul, Lille, France; 17Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia; 18Department of Hematology, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Prague, Czechia; 19Department of Haematology and Hemotherapy, Hospital Ramón y Cajal, Universidad Alcalá Henares, IRYCIS, Madrid, Spain; 20Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy; 21Institute of Pathology, University of Würzburg, Würzburg, Germany; 22Division of Diagnostic Haematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy; 23Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy; 24Incyte Corporation, Wilmington, DE, United States of America; 25Incyte Biosciences International Sàrl, Morges, Switzerland; 26Candiolo Cancer Institute, FPO-IRCCS Candiolo, Turin, Italy